Journal of Gastroenterology and Hepatology最新文献

{"title":"Nutrition","authors":"","doi":"10.1111/jgh.16706","DOIUrl":"https://doi.org/10.1111/jgh.16706","url":null,"abstract":"<p><b>20</b></p><p><b>Risk factors for central line-associated bloodstream infections in home parenteral nutrition patients: an observational cohort study</b></p><p>Paris Hoey<sup>1</sup>, Douglas Roche<sup>1</sup>, Paul Chapman<sup>2</sup>, Vishal Kaushik<sup>1</sup>, Stacey Llewellyn<sup>3</sup> and Niwansa Adris<sup>1</sup></p><p><sup>1</sup><i>Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Australia;</i> <sup>2</sup><i>Department of Infectious Disease, Royal Brisbane and Women's Hospital, Brisbane, Australia;</i> <sup>3</sup><i>QIMR Berghofer Medical Research Institute, Brisbane, Australia</i></p><p><b><i>Background and Aim:</i></b> A central line-associated bloodstream infection (CLABSI) is a common and potentially life-threatening complication for patients with intestinal failure (IF) receiving home parenteral nutrition (HPN). In uncomplicated infections, The European Society for Clinical Nutrition and Metabolism guidelines advocate for central venous access (CVC) salvage for venous access preservation. Existing knowledge regarding the risk factors of HPN-related CLABSIs have been extrapolated from European and North American studies, and the effects of tropical climates and its potentially higher support requirements on the incidence of infection has not yet been studied. We sought to analyse the risk factors of developing HPN-related CLABSI, and assess CLABSI management, in a large Australian state with a highly dispersed population.</p><p><b><i>Methods:</i></b> A retrospective observational cohort study was conducted on 34 adult patients receiving HPN via a CVC at a Queensland tertiary referral centre, between 2016 and 2023. Patient charts were reviewed, and a univariate cox regression analysis model was used to identify predictors of CLABSI in the first CVC. Kaplan-Meier analysis was employed to build survival curves of time to CLABSI, and log-rank tests analysed survival between characteristics.</p><p><b><i>Results:</i></b> Nineteen patients had ≥1 CLABSI(s), accounting for a total of 39 episodes. Patients with ≥1 CLABSI(s) used regular opioids more than those who did not develop CLABSI (p=0.016). Fourteen patients (41%, n=14/34) developed a CLABSI in their first CVC. No patient or line characteristics, including tropical climate, were found to be predictive of CLABSI in their first CVC. The overall infection rate was 1.02 per 1000 catheter days. Most CLABSIs were caused by <i>Enterobacterales</i> (22%, n=12/55), followed by coagulase-negative <i>Staphylococcus</i> (18%, n=10/55). Administration of empiric antimicrobials within the standardised 3-hour sepsis timeframe was inadequate (50%, n=14/28), with only 25% (n=7/28) providing adequate cover of causative pathogens. The median time to effective antibiotic therapy was 22.7 hours (IQR 4.8-29.8). There were 3 CVC salvages (8%, n=3/39), all of which were successful.</p><p><i><b>Conclusion:</b></i> In this cohort of patients, regular opioid ","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.16706","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paediatrics","authors":"","doi":"10.1111/jgh.16707","DOIUrl":"https://doi.org/10.1111/jgh.16707","url":null,"abstract":"<p><b>6</b></p><p><b>Comparing real-world utilisation of dietary and medical therapies in paediatric and adult inflammatory bowel disease patients using CCCare: A cross-sectional study</b></p><p><b>Joseph Pipicella</b><sup>1,2,3</sup>, Wai Kin Su<sup>1,3,4</sup>, William Wilson<sup>5,6</sup>, Jane Andrews<sup>1,7,8</sup> and Susan J Connor<sup>1,2,3,4</sup></p><p><sup>1</sup><i>Crohn's Colitis Cure, Sydney, Australia;</i> <sup>2</sup><i>South West Sydney Clinical Campus, University of New South Wales, Sydney, Australia;</i> <sup>3</sup><i>Ingham Institute for Applied Medical Research, Sydney, Australia;</i> <sup>4</sup><i>Department of Gastroenterology, Liverpool Hospital, South Western Sydney Local Health District, Sydney, Australia;</i> <sup>5</sup><i>SA Health, Adelaide, Australia;</i> <sup>6</sup><i>Lyell McEwin Hospital, Adelaide, Australia;</i> <sup>7</sup><i>Central Adelaide Local Health Network, Adelaide, Australia;</i> <sup>8</sup><i>Faculty of Health Sciences, School of Medicine, University of Adelaide, Adelaide, Australia</i></p><p><b><i>Background and Aim:</i></b> Approximately 10% of people with inflammatory bowel diseases (IBD) are diagnosed in childhood. Crohn’s Colitis Care (CCCare) is an IBD-specific electronic medical record (EMR) used across Australia and New Zealand, with a recent upgrade to incorporate paediatric functionality. Using CCCare, we explored the real-world use of dietary and medical therapies across the age spectrum in people with IBD under routine ambulatory care in ANZ.</p><p><b><i>Methods:</i></b> De-identified data from CCCare’s linked clinical quality registry were analysed in April 2024. All people with IBD under active care (clinical encounter within the prior 14 months) were included. Children were defined as being <18 years of age at time of extraction.</p><p><b><i>Results:</i></b> A total of 6,396 people with IBD were included. In the <18 years age group (n=172), 59.1% (n=101) were male with a median age of 15 years (IQR 12.8-16). The majority (93%, n=93) resided in Australia, and most had Crohn’s disease (66.5%, n=113), with 16.8% of them having ever had a perianal fistula. In the ≥18 years age group (n=6,224), 49.1% (n=3,055) were male with a median age of 42 years (IQR 32-57). The majority (76.5%, n=4,761) resided in Australia, and over half had Crohn’s disease (55.7%, n=113), with 15.9% having ever had a perianal fistula.Interestingly, 5-aminosalicylate use was more prevalent in adults than children (34% vs 27% respectively, P<0.05), whereas current immunomodulator use was less common in adults compared to children (29% vs 60% respectively, P<0.001). Current steroid use was ≤4% in both cohorts (P=0.26). Advanced therapy use by age group is shown below. Anti-TNF therapies (infliximab and adalimumab) were the predominant therapies in the paediatric cohort. Across the cohort, infliximab use decreased with age, whereas vedolizumab use increased with age. Dietary therapies were infrequently us","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.16707","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142231050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Routine GI Endoscopy","authors":"","doi":"10.1111/jgh.16708","DOIUrl":"https://doi.org/10.1111/jgh.16708","url":null,"abstract":"<p><b>8</b></p><p><b>A rare lesion of the oesophagus: oesophageal submucosal gland duct adenoma</b></p><p><b>Gary Zhang</b><sup>1,2</sup>, Spiro Raftopoulos<sup>1,2,3</sup> and Priyanthi Kumarasinghe<sup>1,2,3</sup></p><p><sup>1</sup><i>Sir Charles Gairdner Osborne Park Health Care Group, Perth, Australia;</i> <sup>2</sup><i>The University of Western Australia, Perth, Australia;</i> <sup>3</sup><i>Curtin University, Bentley, Australia</i></p><p><b><i>Introduction:</i></b> Oesophageal submucosal gland duct adenomas (ESGDA) are a rare oesophageal lesion usually diagnosed in males 50-80 years of age presenting with abdominal pain or incidentally. Less than 20 cases of ESGDA have been reported in the literature, with two cases reporting incidental accompanying oesophageal squamous cell carcinoma and gastric adenocarcinoma, respectively.</p><p><b><i>Case report:</i></b> A 68-year-old Caucasian man without other significant medical history presented with mild reflux symptoms. There were no associated alarm symptoms. He was a non-smoker and consumed up to 2 standard drinks of alcohol a day. Initial upper gastrointestinal endoscopy demonstrated a 10mm subepithelial lesion (SEL) at the gastroesophageal junction with normal overlying squamous mucosa and no evidence of reflux changes (figure 1). Pinch biopsies were acquired and reported as an inflammatory polyp with no evidence of dysplasia. The patient was referred for consideration of endoscopic removal following 8 weeks of high dose twice daily proton pump inhibitor therapy. On subsequent endoscopy, the SEL remained despite high dose PPI and therefore a decision was made for endoscopic removal via local excision using a band and ligation technique (figure 1A-C). The lesion was completely resected, retrieved, pinned and sent for pathological assessment. Histopathological assessment of the SEL demonstrated a predominantly submucosal lesion featuring localised hyperplastic and proliferated oesophageal glands and ducts without malignancy (figure 1D). With histochemical stains, the glandular epithelial cells showed diffuse cytoplasmic positivity with epithelial membrane antigen and CK7. Some basal cells showed a positive reaction with p63 and p40. There was no aberrant p53 over-expression or heightened ki-67 proliferation index. The lesion was consistent with an ESGDA. Endoscopic appearances at follow-up demonstrated a smooth, contracted scar (figure 1E).</p><p><b>17</b></p><p><b>Colonoscopy in octogenarians and older patients with 1L polyethylene glycol plus ascorbic acid bowel preparation in the real-world setting</b></p><p>Elena Perez-Arellano<sup>1</sup>, Salvador Machlab<sup>2</sup>, Miguel A Pantaleón<sup>3</sup>, Ricardo Gorjão<sup>4</sup>, Cátia Arieira<sup>5</sup>, Jose Cotter<sup>5</sup>, Vicente Lorenzo-Zúñiga<sup>6</sup>, Sarbelio Rodriguez Muñoz<sup>7</sup>, David Carral-Martínez<sup>8</sup>, Carmen Turbi<sup>9</sup>, Fatma Akriche<sup>10</sup>, José M Esteban<sup>11</sup> and <b>Katherine Davies","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.16708","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of linaclotide in bowel preparation for colonoscopy in patients with constipation: A prospective randomized controlled study","authors":"Haoxin Xu, Zhu He, Yulin Liu, Hong Xu, Pengfei Liu","doi":"10.1111/jgh.16734","DOIUrl":"https://doi.org/10.1111/jgh.16734","url":null,"abstract":"Background and AimColonoscopy plays a crucial role in the early diagnosis and treatment of colorectal cancer. Adequate bowel preparation is essential for clear visualization of the colonic mucosa and lesion detection. However, inadequate bowel preparation is common in patients with constipation, and there is no standardized preparation protocol for these patients. This study aimed to explore the effectiveness and tolerability of a pre‐colonoscopy combination regimen of linaclotide and polyethylene glycol (PEG).MethodsIn this prospective, single‐center, randomized controlled trial, 322 participants were divided into two groups: a 3‐L PEG + 870‐μg linaclotide group (administered as a single dose for 3 days) and a 4‐L PEG group. The primary endpoints were the Boston Bowel Preparation Scale (BBPS) score and the rate of adequate and excellent bowel preparation. Secondary endpoints were the rates of detection of colonic adenomas and polyps, cecal intubation rates, colonoscopy time, adverse reactions, patient satisfaction, and physician satisfaction.ResultsThe study included 319 patients. The 3‐L PEG + linaclotide group showed significantly higher rates of adequate and excellent bowel preparation than the 4‐L PEG group (89.4% <jats:italic>vs</jats:italic> 73.6% and 37.5% <jats:italic>vs</jats:italic> 25.3%, respectively; <jats:italic>P</jats:italic> &lt; 0.05). The mean BBPS score for the right colon in the 3‐L PEG + linaclotide group was significantly higher than that in the 4‐L PEG group. There were no significant between‐group differences regarding the detection rates of colonic polyps and adenomas (44.4% <jats:italic>vs</jats:italic> 37.7% and 23.1% <jats:italic>vs</jats:italic> 20.1%, respectively; <jats:italic>P</jats:italic> &gt; 0.05). There were no significant between‐group differences regarding cecal intubation rates, colonoscopy operation, and withdrawal times. However, patient tolerance and sleep quality were better in the 3‐L PEG + linaclotide group.ConclusionThe combination of 3‐L PEG and 870‐μg linaclotide, because of its lower volume of intake, can be considered as an alternative bowel preparation regimen for constipated patients undergoing colonoscopy, especially for the elderly.","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142195643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CCL25 contributes to the pathogenesis of D-Gal/LPS-induced acute liver failure.","authors":"Fei Sun, Jingwei Wang, Xiangfen Ji, Zhenli Wang, Shuai Gao, Kai Wang","doi":"10.1111/jgh.16732","DOIUrl":"https://doi.org/10.1111/jgh.16732","url":null,"abstract":"<p><strong>Background and aim: </strong>Acute liver failure (ALF) is a fatal clinical syndrome of severe hepatic dysfunction. Chemokines promote liver diseases by recruiting and activating immune cells. We aimed to investigate the role of C-C chemokine ligand 25 (CCL25) in ALF.</p><p><strong>Methods: </strong>An ALF mouse model induced by D-galactosamine/lipopolysaccharide was evaluated through liver hematoxylin and eosin staining and serum transaminase and cytokine measurement. CCL25 expression in serum was analyzed by ELISA and in liver by immunohistochemical staining and western blot. C-C chemokine receptor 9 (CCR9)-expressing cells in the liver were identified by immunofluorescence staining. The effects of anti-CCL25 on ALF were evaluated in vivo. Cytokine expression and migration of CCL25-stimulated RAW264.7 macrophages were studied. We also investigated the role of anti-CCL25 and BMS-345541, an NF-κB signaling inhibitor, in vitro. NF-κB activation was assessed via western blot, and p65 nuclear translocation was detected using cellular immunofluorescence.</p><p><strong>Results: </strong>ALF mice showed severe histological damage and high serum levels of aminotransferase and inflammatory cytokines. Elevated CCL25 and NF-κB activation was observed in vivo. CCR9 was expressed on macrophages in ALF mouse liver. ALF was suppressed after anti-CCL25 treatment, with significant NF-κB inhibition. In vitro, CCL25 induced strong migration and cytokine release in RAW264.7 macrophages, which were eliminated by anti-CCL25 and BMS-345541. Furthermore, the NF-κB activation and p65 nuclear translocation induced by CCL25 were also inhibited by anti-CCL25 and BMS-345541.</p><p><strong>Conclusion: </strong>CCL25 contributes to ALF development by inducing macrophage-mediated inflammation via activation of the NF-κB signaling.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of irreversible pancreatic ductal change triggered by pancreatic duct stenting in chronic pancreatitis.","authors":"Kensuke Takuma, Naoki Okano, Yusuke Kimura, Kensuke Hoshi, Yoichiro Sato, Wataru Ujita, Shuntaro Iwata, Hiroki Nakagawa, Koji Watanabe, Yuto Yamada, Susumu Iwasaki, Yoshinori Igarashi, Takahisa Matsuda","doi":"10.1111/jgh.16733","DOIUrl":"https://doi.org/10.1111/jgh.16733","url":null,"abstract":"<p><strong>Background and aim: </strong>Stent-induced ductal change is a complication of endoscopic pancreatic stent placement for chronic pancreatitis, potentially leading to irreversible changes that may contribute to pancreatic dysfunction. This study aimed to examine the long-term outcomes of stent-induced ductal change and evaluate factors that correlate with the development of irreversible ductal changes.</p><p><strong>Methods: </strong>Between January 2008 and December 2022, 52/223 patients with chronic pancreatitis in whom an S-type plastic stent was successfully placed from the main papilla for duct stricture were detected with stent-induced ductal change on pancreatography at stent removal. We retrospectively investigated the clinical features of patients whose main pancreatic duct was reassessed by endoscopic pancreatography after >1 month without stent and whose residual stent-induced ductal change was irreversible.</p><p><strong>Results: </strong>The patients with chronic pancreatitis with stent-induced ductal change (n = 28) (elevated change, 15; stricture change, 13) were evaluated using follow-up pancreatography. Eleven patients (39.3%) showed residual change associated with stent-induced ductal change, the degree of which was partial improvement, no change, and obstructive change in one, seven, and three patients, respectively. Stricture changes during stent removal and duration of stent placement that triggered ductal changes were significantly associated with the development of residual ductal changes.</p><p><strong>Conclusions: </strong>Irreversible stent-induced ductal change in patients with chronic pancreatitis was associated with stricture changes in the main pancreatic duct and continued plastic-stent placement. Careful evaluation of the pancreatic duct is required during plastic-stent placement. Early plastic-stent removal may result in an effective response to the development of stent-induced ductal change.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review.","authors":"Lauren Eadie, Lindsay A Lo, Michael Boivin, Jagpaul K Deol, Caroline A MacCallum","doi":"10.1111/jgh.16730","DOIUrl":"https://doi.org/10.1111/jgh.16730","url":null,"abstract":"<p><p>There is increasing evidence that cannabidiol (CBD) use is associated with clinically significant liver enzyme (LE) elevations and drug-induced liver injury (DILI). The proportion of LE elevations and DILI events reported in the literature meet the Council for International Organizations of Medical Sciences' (CIOMS) classification of a common adverse drug reaction. However, these potential adverse events are unknown to many clinicians and may be overlooked. The increasing use of CBD for both medical and non-medical use necessitates clear direction in the diagnosis and management of CBD-associated hepatotoxicity. To our knowledge, no such clinical guidance currently exists. For people presenting with elevated LEs, CBD use should be screened for and be considered in the differential diagnosis. This narrative review will provide clinicians with guidance in the prevention, detection, and management of CBD-related hepatotoxicity.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower hepatocellular carcinoma surveillance in metabolic dysfunction-associated steatotic liver disease: Impact on treatment eligibility.","authors":"Connor Henry-Blake, Vinay Balachandrakumar, Mohamed Kassab, Joshua Devonport, Charmaine Matthews, James Fox, Elisabeth Baggus, Alexander Henney, Nicholas Stern, Daniel J Cuthbertson, Daniel Palmer, Philip J Johnson, David M Hughes, Theresa J Hydes, Timothy J S Cross","doi":"10.1111/jgh.16727","DOIUrl":"https://doi.org/10.1111/jgh.16727","url":null,"abstract":"<p><strong>Background and aim: </strong>This study aimed to compare the determinants and impact of hepatocellular carcinoma (HCC) surveillance rates for people with metabolic dysfunction-associated steatotic liver disease (MASLD) versus other chronic liver diseases.</p><p><strong>Methods: </strong>A dataset of HCC patients from a UK hospital (2007-2022) was analyzed. The Mann-Whitney U-test compared continuous variables. The χ² and two-tailed Fisher exact tests compared categorical data. Regression modeling analyzed the impact of MASLD on the size and number of HCC nodules and curative treatment. The Cox proportional hazards model assessed the influence of MASLD on overall survival.</p><p><strong>Results: </strong>A total of 176 of 687 (25.6%) HCC patients had MASLD. Fewer people with MASLD HCC were enrolled in HCC surveillance compared to non-MASLD HCC (38 [21.6%] vs 215 [42.1%], P < 0.001). Patients with MASLD HCC were less likely to have been under secondary care (n = 57 [32.4%] vs 259 [50.7%], P < 0.001) and less likely to have cirrhosis (n = 113 [64.2%] vs 417 [81.6%], P < 0.001). MASLD was associated with a 12.3-mm (95% confidence interval [CI] 10.8-14.0 mm) greater tumor diameter compared to people without MASLD (P = 0.002). Patients with MASLD HCC had 0.62 reduced odds (95% CI 0.43-0.91) of receiving curative treatment compared to non-MASLD HCC (P = 0.014). Overall survival was similar for patients with MASLD HCC versus non-MASLD HCC (hazard ratio 1.03, 95% CI 0.85-1.25, P = 0.748).</p><p><strong>Conclusion: </strong>Patients with MASLD are less likely to have been enrolled in HCC surveillance due to undiagnosed cirrhosis or presenting with non-cirrhotic HCC. Patients with MASLD HCC present with larger tumors and are less likely to receive curative treatment.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastrointestinal: Annular pancreas: duodenal ampulla cancer.","authors":"J Cao, L Sha, J Wang","doi":"10.1111/jgh.16691","DOIUrl":"https://doi.org/10.1111/jgh.16691","url":null,"abstract":"","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: In vitro digestion and radiolabeling characteristics of Vital^® for gastric emptying scintigraphy.","authors":"N Tagiling, H W Ngo, N-F Sahran, M D Mohamad Kamarulzaman, Mp-K Wong, N Mustaffa, S H Syed Abd Aziz, Y Y Lee, N Mat Nawi","doi":"10.1111/jgh.16729","DOIUrl":"https://doi.org/10.1111/jgh.16729","url":null,"abstract":"","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}